Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnology's chronic hepatitis delta ...

SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...

Hello, and welcome to Vir Biotechnology's Third Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded. [Operator Instructions] I will now turn ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...

Firefly Aerospace Inc. (NASDAQ:FLY) Q2 2025 Earnings Call Transcript September 23, 2025 Operator: Greetings. Welcome to the Firefly Aerospace Second Quarter 2025 Financial Results Conference Call.

The reporters reviewed the hundreds of items in the bill and their corresponding C.B.O. scores. Source: New York Times analysis of Congressional Budget Office estimates. Note: Amounts are net totals ...

The Eclipse Foundation has released the latest version of its enterprise Java application platform in Jakarta EE 11, promising simpler data access, streamlined testing processes, and Java 21 support.

Jakarta EE, a working group hosted by the Eclipse Foundation, today announced the general availability of the Jakarta EE 11 Platform, the latest version of its enterprise Java platform. The new ...